Breaking News

Israeli ALS treatment designated “fast-track” by FDA

Thumbnail for 102531

An MRI of the brain indicating ALS. Credit: Frank Gaillard via Wikimedia Commons.

( Stem cell treatment developed by Israeli company BrainStorm Cell Therapeutics has been designated by the U.S. Food and Drug Administration (FDA) as a “fast-track” treatment of amyotrophic lateral sclerosis (ALS).

The treatment, titled NurOwn, is currently undergoing mid-stage clinical trials in Jerusalem and in the U.S. on patients with ALS, which is also known as Lou Gehrig’s Disease. The FDA’s designation will speed up patients’ access to the treatment.

“The receipt of fast-track designation from the FDA is an acknowledgement of the unmet medical need in ALS,” BrainStorm Chief Executive Tony Fiorino said Tuesday according to Reuters.

“What is so valuable about fast track designation to a small company like BrainStorm is the opportunity to have increased meetings with and more frequent written communication from the FDA,” he said. He added that few other cellular therapies have received FDA approval.

The ALS Association reports that 5,600 people in the U.S. are diagnosed each year with ALS.

Powered by WPeMatico

Please ShareShare on FacebookTweet about this on TwitterShare on Google+Share on LinkedInShare on StumbleUponPin on PinterestEmail this to someone

Jewish Content

Posted by on October 8, 2014. Filed under Breaking News,Israeli News,Slider. You can follow any responses to this entry through the RSS 2.0. Both comments and pings are currently closed.